TL;DR: TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4, a natural repair protein present in nearly every cell. Its mechanism is unusual — it binds actin, a structural protein inside the cell, rather than acting on a surface receptor, which places it upstream of many repair processes at once. The evidence is preclinical, it is not approved for human use anywhere, and it is prohibited in competitive sport. Supplied for research use only.
What TB-500 Is
TB-500 is a short synthetic peptide built around the active, actin-binding region of Thymosin Beta-4 (Tβ4) — a 43-amino-acid protein present in almost every cell type and heavily involved in repair, cell migration, and inflammation.
Rather than synthesize the entire protein, researchers use TB-500 as a stable and far cheaper stand-in for studying the Tβ4 pathway. Producing a 43-amino-acid protein reliably is difficult and expensive; producing a short peptide that reproduces its active site is neither.
TB-500 Is Not Thymosin Beta-4
This distinction gets collapsed constantly, including by suppliers, and it is worth holding onto.
Thymosin Beta-4 is the full natural protein your cells actually produce. TB-500 is a synthetic fragment reproducing its active region. They share a mechanism, but they are different molecules with different sizes and different pharmacokinetic behaviour.
The practical consequence: a study conducted on Tβ4 is not automatically a study of TB-500, and vice versa. Much of the confident material written about TB-500 online is quietly citing Tβ4 research. When reading claims about either, checking which molecule was actually used is the single most useful filter available.
How It Works: Actin, Not a Receptor
The defining feature of TB-500 is mechanistic. Nearly every research peptide discussed on this site works by binding a receptor on the cell surface and triggering a signalling cascade inside. TB-500 does not.
Instead it binds G-actin — the monomeric building block of the cell's cytoskeleton — and influences how actin filaments assemble and disassemble.
Actin is the cell's structural scaffolding and its means of locomotion. It determines how a cell holds its shape, how it crawls toward a wound, how it divides, and how it specializes. Regulating actin therefore sits upstream of a great many processes rather than inside any one of them.
Most peptides act on one pathway. TB-500 acts on the machinery that many pathways depend on — which explains why it turns up across so many different repair models, and why its effects are harder to characterize precisely.
That breadth cuts both ways. It is why TB-500 appears in muscle, tendon, corneal, cardiac, and dermal research simultaneously, and it is also why isolating a clean, specific effect has proven difficult.
What It Is Studied For
In animal and in-vitro work, TB-500 appears across several repair contexts.
| Research area | What is being investigated |
|---|---|
| Muscle | Repair and recovery models following induced injury |
| Tendon and ligament | Connective-tissue repair, where native healing is slow and poorly vascularized |
| Wound healing | Cell migration into damaged tissue — the most direct expression of the actin mechanism |
| Vascular | Angiogenesis, the formation of new blood vessels supporting repair |
| Cardiac | Post-ischemic models, drawing on Tβ4 literature |
All of this is preclinical, mechanism-level research. None of it constitutes evidence of a human therapeutic effect, and no completed human trial supports any of these applications.
TB-500 vs BPC-157
These two are the most commonly compared research peptides in the repair category, and the comparison is more useful once the mechanisms are separated.
| TB-500 | BPC-157 | |
|---|---|---|
| Origin | Fragment of Thymosin Beta-4 | Fragment derived from a gastric protein |
| Mechanism | Binds G-actin; regulates cytoskeletal assembly | Associated with angiogenesis and growth-factor signalling |
| Emphasis in literature | Cell migration and structural repair | Vascular and gastrointestinal repair models |
| Human trials | None completed | None completed |
They are not alternatives to one another in research terms — they are different tools. Our what is BPC-157 explainer covers the other side in depth.
The "Wolverine Stack" Pairing
TB-500 is frequently studied alongside BPC-157, a pairing nicknamed the "Wolverine stack." The rationale is mechanistic rather than promotional: because the two act through separate pathways, combining them is a way to probe whether repair outcomes improve when several routes are engaged at once, rather than simply increasing the dose of one.
Whether the combination genuinely outperforms either alone is not settled by the published record. Our BPC-157 + TB-500 synergy article works through what the literature does and does not support. Helix North stocks the combination as a pre-blended research vial, listed on the BPC-157 Canada page.
Regulatory and Sport Status
Two facts worth stating plainly. TB-500 is not approved for human use by the FDA, Health Canada, or any comparable regulator — there is no completed human trial programme behind it. Separately, it is prohibited in competitive sport under the World Anti-Doping Agency code, which is why it appears periodically in sanction reports.
It remains legal to purchase and possess in Canada as a research material, and that is the only capacity in which it is supplied.
Handling and Storage
TB-500 ships lyophilized and is reconstituted with bacteriostatic water. Add the diluent slowly down the inside wall of the vial and swirl gently rather than shaking — mechanical agitation can shear peptide chains. Refrigerate at 2 to 8 degrees Celsius after reconstitution; lyophilized vials store well frozen long-term.
Our reconstitution guide walks the concentration math step by step, the storage guide covers stability, and the peptide reconstitution calculator converts any vial and diluent combination into syringe units.
Helix North supplies TB-500 10 mg as a research material with batch-specific HPLC purity verification. See the TB-500 Canada guide for forms, purity, and domestic sourcing.
For Research Use Only
Everything above describes preclinical laboratory research on a compound with no completed human trials and no regulatory approval. Helix North supplies TB-500 for research applications only — not for human or animal consumption, and nothing here constitutes medical, dosing, or clinical guidance.
